Immusmol
Pierre-Emmanuel Gaultier serves as the Marketing & Communication Manager at ImmuSmol and Explicyte, both since February 2024, and holds the position of Responsable Marketing & Communication at Nobel Therapeutics. Previously, Pierre-Emmanuel was the Marketing Communication Director at Toopi Organics, where innovative biostimulants derived from human urine were developed as alternatives to chemical fertilizers. Additionally, Pierre-Emmanuel has experience as a Marketing & Communication Manager at TreeFrog Therapeutics, a co-founder at L'Apérissier, and the founder of A to B Communication, a science and technology communication agency. Early in the career, Pierre-Emmanuel worked with Fluofarma and the European Institute of Chemistry and Biology, contributing to various marketing and communication roles. Academic credentials include master's degrees in Communication, Advertising and Public Relations from Ulster University and Philosophy from Nantes Université, along with a bachelor's degree in Philosophy from the University of Leeds.
This person is not in the org chart
This person is not in any teams
Immusmol
Immusmol develops small molecule antibodies for research, diagnostics and therapy. Combining 25 years of experience in antigen design, we offer to target low molecular weight molecules, which are not usually addressed by antibodies, such as amino acid metabolites, lipids, saccharids, toxins, pesticide residues, small molecule drugs, ... Compatible with existing antibody-based technologies, our small molecule antibodies can serve for: > VISUALIZATION: Small molecule antibodies currently represent the only applicable technology for the visualization of small molecules in cells and tissues by IF or IHC. > QUANTIFICATION: Combined with ELISA/EIA technologies, small molecule antibodies enable rapid and robust detection of small molecules in biological samples (an attractive alternative to mass-spec and aptamer-based technologies). > MODULATION: Small molecules represent a vast class of neglected drug targets. ImmuSmol is currently developing a pipeline of proprietary monoclonal antibodies interfering with endogenous small molecules involved in cancer and CNS disorders.